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Abstract
Background: Metabolomics has been proven to be an invaluable research tool by 
providing comprehensive insight into systemic metabolism. However, the lack of 
scalable and quantitative methods with known reference intervals (RIs) and docu-
mented reproducibility has prevented the use of metabolomics in the clinical setting.
Objective: The objective of this study was to validate the developed quantitative 
nuclear magnetic resonance (NMR) spectroscopy- based metabolomics platform for 
canine serum and plasma samples and determine optimal sample handling conditions 
for its use.
Methods: Altogether, 8247 canine samples were analyzed using a Bruker's 500 MHz 
NMR spectrometer. Using statistical approaches derived from international guide-
lines, we studied method precision, measurand stability in various long- and short- 
term storage conditions, as well as the effect of prolonged contact with red blood 
cells (RBCs), and differences among blood collection tubes. We also screened in-
terferences with lipemia, hemolysis, and bilirubinemia. The results were compared 
against routine clinical chemistry methods, and RIs were defined for all measurands.
Results: We determined RIs for 123 measurands, most of which were previously un-
published. The reproducibility of the results of the NMR platform appeared generally 
outstanding, and the integrity of the results can be ensured by following standard 
blood drawing and processing guidelines.
Conclusions: Owing to the advantages of quantitative results, high reproducibility, 
and scalability, this canine metabolomics platform holds great potential for numerous 
clinical and research applications to improve canine health and well- being.
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1  | INTRODUC TION
Metabolomics is an omics- based approach that generates compre-
hensive information of metabolism, enabling an extensive view on 
the current state of system metabolism. Metabolomics has become 
increasingly popular in canine studies. It has been used to charac-
terize the metabolic effects of multiple environmental factors, and 
inter- and intra- individual factors, including feeding, aging, inter- 
breed differences, drug action, behavior, exercise, genetic factors, 
and pathologic processes.1
Mass spectrometry (MS) and proton nuclear magnetic resonance 
(NMR) spectroscopy are the two main metabolomics technolo-
gies.2 NMR spectroscopy offers cost- effectively quantitative data 
with high reproducibility, high throughput, and excellent scalabil-
ity.2 NMR spectroscopy is well suited for the scientific use of large 
cohorts and biobanks,3,4 and is highly suited for studies combining 
different omics technologies.4,5 Due to the quantitative and highly 
reproducible nature of NMR spectroscopy, this technique can be 
easily used as a diagnostic tool, offering research findings to be eas-
ily applied for clinical use.
Metabolomics holds great potential for clinical diagnostics. It 
is proving to be valuable for disease risk predictions.6- 10 For ex-
ample, in human type 2 diabetes mellitus, metabolic changes have 
been found to occur years before disease onset, enabling support-
ive and preventive measures before clinical manifestations occur.10 
Metabolomics is also viewed as a potential tool for the evaluation 
of disease severity and differential diagnostics.10,11 The metabolic 
state of an individual might also impact the best treatment of a 
patient, affecting drug responses, drug toxicities, treatment effi-
cacies, and nutritional needs.11- 13 Especially, the management of 
chronic metabolic diseases is thought to benefit from a method ca-
pable of generating comprehensive information on the metabolic 
state of an individual, enabling a personalized approach to disease 
management.10 In contrast to genetics, metabolomics offers real- 
time information about the metabolic state of an animal, taking 
environmental factors and treatments into account. This offers 
metabolomics the ability to be used as both a diagnostic and fol-
low- up tool.
Prerequisites for the utility of a particular method include 
the documentation of method reproducibility, an understanding 
regarding the factors influencing the results, and the formation 
of reference intervals (RIs).14,15 All of these factors remain largely 
unpublished in the canine metabolomics field. The objectives of 
this study were to conduct the method validation studies most 
appropriate for the clinical use of the method and determine the 
most appropriate sample handling practices for its use. To achieve 
this, we determined analytic precision and RIs for all measurands. 
We also, conducted an interference screen and a method compar-
ison study, and studied storage stability, the effects of prolonged 
contact with red blood cells, and the differences between sample 
tubes.
2  | MATERIAL S AND METHODS
2.1 | Proton NMR spectroscopy
The (NMR) metabolomics technique is similar to the technique used 
in human samples.16 The highly automated process uses a Bruker 
AVANCE III HD 500 spectrometer with a 5 mm triple- channel (1H, 
13C, 15N) z- gradient Prodigy probe head (Bruker Biospin) capable 
of quantifying 200 samples every 24 hours. Usable sample types are 
serum, EDTA plasma, heparinized plasma, and citrated plasma.
The laboratory that performed the NMR analyses complied with 
the EN ISO 13485:2016, SFS- EN ISO/IEC 17025:2017, and SFS- EN ISO 
15189:2013 standards.17- 19 It has several quality assurance processes 
to ensure high- quality results, including constant performance testing 
of analytic equipment, monitoring sample preparation, and assessing 
quality using quality control (QC) samples. Two plasma QC samples 
are included in each 96- sample rack, and a technical control sample 
is profiled with each NMR instrument at regular intervals. The control 
sample data are reviewed and reported periodically. Furthermore, au-
tomated data processing procedures check for unexpected signals and 
irregularities. Integrated procedures verify the quality of each sample 
by reporting signs of sample degradation and contamination. If mea-
surand levels are below the limit of detection, the value is presented as 
missing. Since the entire testing process is highly automated, operator- 
to- operator variability can be regarded as negligible.
To develop, validate, and use this method in dogs, the canine 
NMR metabolomics project was initiated. A total of 8247 serum or 
plasma samples were analyzed from fall 2016 to fall 2018 (Figure S1), 
with samples obtained from 6164 individual client- owned dogs 
(Table 1). Most samples were collected by cephalic venipuncture 
during organized sampling times; 439 samples were collected at 
Finnish veterinary clinics and sent to this project by mail as EDTA- 
anticoagulated whole blood; 999 samples were routine diagnostic 
material from a veterinary laboratory. Samples were frozen at −80℃ 
after plasma/serum separation within 15 minutes and 240 hours of 
collection and stored there for 1 week to 1 year before NMR anal-
ysis. For all purposefully collected samples, the owners completed 
a history form, including the dog's signalment and details about the 
health status, diet, exercise, stress, and reproductive state.
Initial method calibration was conducted using 847 EDTA plasma 
samples and 120 serum samples. The characteristic NMR signals of 
amino acids, glycolysis- related metabolites, creatinine, and glycopro-
tein acetyls (GlycA) are well- known, and the quantitative and linear 
relationship between signal intensities and molecular concentrations 
is an inherent property of NMR. Thus, these measurands can be 
quantified using the established NMR techniques. The signal identifi-
cation of triglycerides, cholesterol, and lipoproteins was verified and 
calibrated by analyzing 200 EDTA plasma samples with different lipid 
concentrations using high- performance liquid chromatography,20 and 
fatty acids were similarly analyzed with 100 samples in a commercial 
laboratory (Vitas as, Norway) using a chromatographic method.
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2.2 | Precision
The precision of the NMR platform was evaluated using the one- run- 
per- day procedure from Clinical & Laboratory Standards Institute 
(CLSI) EP5- A3.21 Since it was not feasible to collect samples at clini-
cal decision limits for all measurands, we chose to use three dogs in 
different physiologic states (puppy, adult, and senior dog suffering 
from hyperadrenocorticism). Blood was drawn by cephalic venipunc-
ture into Vacuette 8 ml Z Serum Sep Clot Activator tubes (Greiner 
Bio- One). After clotting for 30- 45 minutes, the samples were centri-
fuged at 2000g for 10 minutes to separate serum. Every sample was 
divided into 40 aliquots of 100 µL and stored at −80℃ for 1 week to 
2 months. Two duplicate aliquots of each sample were analyzed each 
day during a 20- day time period.21
The sample from the senior dog suffering from hyperadrenocor-
ticism showed marked chylomicronemia and was used to evaluate 
the effect of chylomicronemia on analytical precision.
Total within- laboratory precision estimates were expressed as 
both the coefficient of variation (CV%) and standard deviation (ST). 
Within- run precision was expressed as the within- run standard de-
viation (Sr). Combined between- day and between- run precision were 
expressed as the standard deviation of the daily means (B). Outlier de-
tection was based on the differences in the duplicate aliquots in the 
same run compared with the mean difference of all duplicates from 
the sample. A difference that exceeded the mean difference fourfold 
was set as the rejection line for the exclusion of the duplicates.
The most advisable hierarchy for performance goals in human 
diagnostic laboratories include (1) biological outcomes, (2) biologi-
cal variation, and (3) state- of- the- art goals.22,23 Biological outcome- 
based performance goals are yet unpublished for animals, and both 
biological variation- and state- of- the- art goals have their own pit-
falls. Thus, we evaluated the precision estimates against a set of pre-
cision goals:
1. Biological variation- based CV% goals (CVBV).
24 These goals have 
drawbacks in that they can be too strict, unachievable by 
clinical laboratories, and do not affect result interpretations.25
2. Total allowable error (TEa) goals based on clinical decision limits 
(CVCDL). The total error of veterinary laboratory results is evaluated 
using observed total error (TEobs), which is then evaluated against 
preset TEa limits. TEobs can be calculated as TEobs = Bias% + 2 
CV%. Bias was not applicable for this study as a deviation from 
a true value.25 This led us to use ½ of the American Society for 
Veterinary Clinical Pathology (ASVCP) TEa limits based on CVCDLs 
as a precision goal for the CV%.
3. For measurands where biological variation- or TEa- based goals 
were unavailable, we used 20% as the CV% goal (CVBG), which 
is generally considered an acceptable error in metabolomics.26,27 
However, this goal might not be descriptive for measurands with 
very wide or narrow reference intervals caused by inter- individual 
biological variation.
4. A comparison of the ST to the ST goal of under 1/8 refer-
ence widths (STmax). This goal was set since analytical varia-
tion over one- quarter of the reference interval could affect 
clinical interpretation.28 However, this goal has a draw-
back in that imprecision affects the width of the reference 
interval.29
2.3 | Interference screen
We performed interference screens for hemolysis, lipemia, and un-
conjugated and conjugated bilirubin with a protocol derived from 
CLSI- EP7- A2.30 Interference was evaluated on primary measurands, 
not ratio and percentage measurands. Lipemia interference was only 
evaluated for molecules other than lipids since the lipid removal pro-
cess inevitably decreases lipid concentration.
For hemolysis interference screening, 5 mL of heparinized blood 
was collected from two client- owned dogs by cephalic venipuncture. 
The samples were centrifuged, and plasma was separated and dis-
carded. Hemolysates were prepared from the red blood cells using 
the osmotic shock procedure, and hemoglobin concentrations were 
measured using an ADVIA 2120i hematology analyzer (Siemens).31 
The base of the test and control samples was created by collect-
ing 5 mL heparinized blood by cephalic venipuncture from the same 
dogs. To produce test samples containing 500 mg/dL hemoglobin, 
a measured volume of hemolysate from one dog was added to the 
plasma of the same dog.
TA B L E  1   Demographics of the dogs in this study
Dogs, n Breeds, n Males%/females% Puppies % (n) Adults % (n)
Seniors 
% (n)
Alla,b  6164 256 40/60 18 (1094) 61 (3764) 21 (1303)
Seruma  4816 223 40/60 18 (886) 60 (2871) 22 (1057)
Heparinized plasma 498 117 40/60 13 (67) 63 (315) 23 (116)
1031 158 42/58 15 (153) 67 (686) 18 (191)
Note: Demographics of individual client- owned dogs with samples collected during the canine NMR metabolomics project. Some individuals had 
replicate samples taken or samples of multiple sample types. The table does not include the leftover clinical laboratory samples used in the method 
comparison study. Puppies were aged <1 year, adults 1- 7 years and seniors >7 years.
aThe ages of two dogs were unknown in the serum group.
bThe age of one dog was unknown in the EDTA plasma group.
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Bilirubin interference was screened by creating two sample pools 
with measurand concentrations that were as different as possible. 
Baseline bilirubin concentrations were measured (540 nm) using a 
modified version of the acid diazo coupling (Malloy- Evelyn) method 
(Bilirubin Total (NBD), Thermo Fisher Scientific) and a Konelab 60i 
chemistry analyzer (Thermo Fisher Scientific).32 The two pools were 
divided into four pools, creating the bases for separate test and con-
trol pools for unconjugated and conjugated bilirubin. The test pools 
for conjugated bilirubin were prepared by adding the 201102 EMD 
Millipore bilirubin conjugate (Sigma- Aldrich), and unconjugated bili-
rubin was prepared by adding 2011 EMD Millipore bilirubin (Sigma- 
Aldrich). All pools were in 20 mg/dL concentrations. The control 
pools for conjugated and unconjugated bilirubin were prepared by 
adding the same volume of water or NaOH, respectively.
Lipemia interference was screened by pooling lipemic serum 
samples to create a pool with a triglyceride concentration around 
2 mmol/L. The samples had been previously stored at −80℃ for 
1- 2 years. The created pools were divided into test and control pools, 
and lipids in the control pool were cleared by ultracentrifugation.
All resulting samples/pools were divided into triplicate aliquots, 
and could detect interference effects over 3.0× within- run preci-
sion with 95% confidence and power.30 The bilirubin interference 
was analyzed in samples within a day whereas hemolytic samples 
were stored at −80℃ for 2 days, and lipemia samples were stored for 
2 weeks before NMR analysis.
Statistical testing was based on point estimate comparisons of 
the observed interference effect (dobs) and the cutoff value (dc), ac-
cording to CLSI- EP7- A2.30
The interference effect, dobs, was defined as the difference be-
tween the means of the test and control samples:







where dnull represents the assumed difference between the means 
of test and control samples (set to 0), n is the number of replicates 
(n = 3), and s is the mean repeatability standard deviation (Sr) of non- 
chylomicronemic samples obtained from the precision study. We 
calculated 95% confidence intervals for dobs as follows:
We established our decision of interference on the lower 95% 
limit of interference cutoff value (dobs_low). Interference was present if 
dobs_low > dc in at least one sample/pool since matrix properties and/or 
measurand concentrations might affect the presence of interference.
2.4 | Method comparison
The method comparison study was designed to evaluate whether 
the results of routine clinical chemistry measurands included in the 
NMR metabolomics platform were interchangeable with the results 
obtained using a conventional clinical chemistry method. Bias was 
viewed as a measure of method interchangeability since the values 
obtained by the conventional method cannot be regarded as true 
measurand values.
The used samples (n = 999) were routine diagnostic canine sam-
ple material submitted by veterinarians across Finland, sent by mail 
to a single laboratory (Movet Oy). Upon arrival, the samples were di-
vided into two aliquots. One aliquot was immediately analyzed with 
a Thermo Fischer Scientific Konelab Prime 60i chemistry analyzer 
(Thermo Fisher Scientific) using automated methods. Triglycerides, 
cholesterol, and creatinine were measured by enzymatic methods, 
albumin by a photometric method using bromcresol green, glucose 
by the IFCC- standard method using hexokinase, and lactate by a 
colorimetric method using lactate oxidase. QC for the conventional 
method measurands included two QC sample measurements at dif-
ferent levels before running the samples. For creatinine, only one 
QC sample was analyzed. The QC procedure was conducted follow-
ing the QC limits (±2 SD) provided by the control manufacturer.
The other aliquot was frozen and stored at −20℃ for a maxi-
mum of 4 weeks before shipment for the NMR analysis. The samples 
were sent in three batches on freezer blocks with a shipping time 
of 7- 14 hours. At the NMR laboratory, the samples were stored at 
−80℃ for a maximum of 1 week before analysis. One of the sam-
ple shipments was sent over a 14 h period on freezer blocks and 
partly thawed during shipment. The NMR albumin measurement 
was scaled using 404 samples; these samples were excluded from 
the albumin method comparison.
Statistical analysis followed the ASVCP principles of quality 
assurance and standards.15 Comparison plots were created for 
raw data, logarithm- transformed data, and Deming- transformed 
data. Deming regression33,34 was used to calculate the slope and 
intercept for all measurands and linear regression for measurands 
with a correlation over 0.99. The mean bias was determined at 
both ends of the reference interval using the slope and intercept. 
Bland- Altman plots35 were used to visualize the distribution of dif-
ferences. To determine method interchangeability, total observed 
error (TEobs) was evaluated against ASVCP clinical chemistry guide-
lines’ total allowable error goals (TEa) based on clinical decision lim-
its,25 which reflect the maximum values that would affect clinical 
decision- making.
2.5 | Sample storage study
In the sample storage study, we examined the effects of both long- 
and short- term sample storage conditions on analytic results. The 
sample storage study protocol is presented in Table S1. Measurand 
stability was studied only in primary measurands, not in ratio and 
percentage measurands.
Serum and EDTA plasma samples from seven client- owned dogs 
and heparinized plasma samples from four dogs were collected in 
separate sampling situations. Samples were drawn by cephalic 
dobs = xtest − xcontrol
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venipuncture, centrifuged, and separated according to the tube 
manufacturer's recommendations. The samples were divided into al-
iquots and stored in the test conditions (Table S1). Serum and EDTA 
plasma samples were analyzed by NMR immediately after storage in 
the different test conditions, whereas heparinized plasma samples 
were additionally stored at −80℃ for 2- 3 weeks.
We used the two- sided Wilcoxon's exact test to estimate the 
statistical significance of the changes in measurand values between 
samples not subjected to storage (T0) and samples subjected to dif-
ferent storage conditions at each storage time point (Tx) (Table S1). 
In addition to the Wilcoxon test, we calculated the mean percentage 
deviation (MPD) using the following formula to indicate the magni-
tude of the change36:
MPD was compared with the acceptable change limit (ACL), ac-
cording to ISO 5725- 6, and calculated using the following formula37:
The CVa was obtained from the precision study results of this 
study and calculated as the mean CV% of the nonchylomicronemic 
samples. The factor 2.77 was derived from 1.96 × √2, where 1.96 
represents the 95% confidence interval for bi- directional changes, 
and √2 was used since we compared two results with the same CVa. 
An MPD higher than the ACL represents a probable change in mea-
surand concentration.
Outlier detection cut points were defined as:
where Tx−T0 is the mean and STD(Tx−T0) is the standard deviation of 
the difference in measurand results at storage time Tx and collection 
time T0.
If the difference Txi − T0i of the sample i exceeded or undercut 
these cut points, it was defined as an outlier. All analyses were per-
formed as both outliers included and excluded to evaluate the effect 
of outlier exclusion.
The criteria for clinically significant change were set so that the 
change would be both statistically significant (Wilcoxon P < 0.05) 
and the magnitude of the change, evaluated as MPD, would exceed 
the ACL. The change was required to be consistent at the remaining 
time points.
2.6 | Delayed plasma separation study
In the delayed plasma separation study, we defined how 24- and 48- 
hour delays in plasma separation affect measurand values.
Blood was drawn by cephalic venipuncture from 34 client- 
owned dogs into three Vacuette K2 EDTA tubes per dog. One of the 
tubes was centrifuged, and plasma was separated within 1 hour of 
sampling. The remaining two tubes were stored as whole blood in 
a refrigerator until centrifugation, and plasma was separated after 
24 and 48 hours. After plasma separation, all samples were stored 
at −80℃ for 1- 1.5 years before NMR analysis. This experiment was 
conducted using an older version of the NMR platform, with a lower 
number of measurands, lacking fatty acids, for example.
Statistical methods were the same as in the sample storage 
study. T0 in the delayed plasma study represented plasma separated 
according to the sample tube manufacturer recommendations, and 
Tx plasma separated after 24 and 48 hours.
2.7 | Sample tube validation
To study whether different blood collection tubes affect measurand 
values, we studied differences between different blood collection 
tubes and their lots. The protocol was modified from the proposed 
process by Bowen and Adcock38 and was conducted only for pri-
mary measurands, not for ratio and percentage measurands.
Thirty milliliters of blood were drawn from an intravenous cannula 
in the cephalic vein of 20 dogs into seven different types of blood 
collection tubes (Table S2), each tube type having two tubes from 
different lots. All samples were centrifuged and separated according 
to sample tube manufacturer's recommendations. The centrifugation 
conditions for the MiniCollect tubes were 3000g for 10 minutes and 
for all other tube types were 2000g for 13 minutes. All samples were 
stored at −80℃ for 1- 2 months before NMR analysis.
Differences between different sample tubes were tested using 
this protocol
1. Study where the tubes give comparable results to the primary 
reference tube; the Vacuette lithium heparin tube was set as 
the primary reference tube (T0), and all other tubes (Tx) were 
compared against it.
2. Study where the serum tubes give comparable results to the 
serum reference tube (as we hypothesized, that most of the dif-
ferences between sample tubes would originate from differences 
between serum and plasma): the Vacuette Z Serum Clot Activator 
tube was set as the serum reference tube (T0) and all other serum 
tubes (Tx) were compared against it.
The average of the measurand values in the two lots was used 
in these calculations. Lot- to- lot variability was tested using this 
protocol
1. Compare the two lots of each tube to one another; tubes in 
lot A were set as the reference tubes (T0), and tubes in lot 











± 2 ⋅ STD
(Tx−T0)
,
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2. If lot- to- lot variability was observed, results of each lot were com-
pared with the reference tubes to determine if samples from both 
lots would give comparable results to the other tube types.
Lots A and B were compared separately to the Vacuette Lithium 
Heparin and Vacuette Z Serum Clot Activator tubes.
Similar statistical methods were used as in the sample storage 
study. For the outlier detection protocol, the coefficient of 3 for the 





∓ 3 ⋅ STD
(Tx−T0)
. We chose this STD since outlier 
testing was more sensitive due to more observations in this study.
In addition to the statistical methods being similar to the storage 
study, we calculated bias as the mean difference of Tx and T0 with 
95% confidence intervals to highlight the limits where the differ-
ences reside.
Although measurand quantification is possible from citrate 
tubes, we did not include this tube type in our study, since this tube 
type is typically not used in clinical applications of this field.
2.8 | Reference intervals
Determination of RIs was performed according to the American 
College of Veterinary Clinical Pathology (ASVCP) reference 
interval guidelines.14 Inclusion in the RI calculation was based 
on fasting duration (minimum of 12 hours), appropriate sample 
handling, and the lack of owner- reported biological confounding 
factors, including diseases, severe anxiety/stress, and strenuous 
exercise.
We used the population- based nonparametric method for RI cal-
culation to calculate reference limits as 2.5th and 97.5th percentile 
limits and calculated 90% confidence intervals (CIs) for the reference 
limits. The lower reference limit, r1, was computed as the observa-
tion corresponding to r = 0.025 (n + 1), and the upper reference limit, 
r2, as the observation corresponding to r = 0.975 (n + 1). When the 
values of r1 and r2 were not integers, the limits were calculated by 
interpolating between the data points corresponding to the ranks 
on either side of r1 and r2. The 90% CIs for the reference limits 
were assigned according to the published sample size- specific rank 
numbers.
A total of 865 serum samples collected for the canine NMR me-
tabolomics project were included in the serum RI calculations. The 
samples were chosen to include over 120 samples of puppies (under 
1 year old), adults (1- 7 years old), and senior dogs (over 7 years old) 
for age- specific RI calculations. The 865 samples consisted of indi-
viduals from 68 breeds; 347 males and 517 females, with 152 pup-
pies, 545 adult dogs, and 168 senior dogs.
A total of 269 samples out of the initial 495 samples collected 
for the canine NMR metabolomics project were qualified for lith-
ium heparinized plasma RI determinations. These samples consisted 
of individuals from 83 breeds; 155 males and 114 females, with 29 
puppies, 196 adult dogs, and 44 senior dogs. Age- specific RIs were 
calculated for the adult dogs.
Each measurand was examined for outliers. We used Box- Cox 
transformations to find normal transformations and Horn's algo-
rithm in the transformed data to identify outliers. Values were 
considered outliers if they exceeded interquartile (IQ) fences set 
at Q1 − 1.5*IQR and Q3 + 1.5*IQR (IQR = interquartile range; 
IQR = IQ3 − IQ1, where IQ1 and IQ3 are the 25th and 75th per-
centiles, respectively). After outlier identification, the sample and 
animal data were thoroughly reviewed for confounding factors be-
fore reaching a conclusion about sample exclusion. In measurands 
with non- normal distributions after data transformation, Horn's al-
gorithm offered multiple outliers, which were all reviewed before 
reaching a conclusion about exclusion.
Lastly, we studied the relation between 90% CIs of the reference 
limits and RIs. It is recommended that CIs should not exceed 0.2 times 
the width of the RI since it might indicate insufficient sample numbers.
All calculations and plotting conducted throughout this study 
were performed using SAS version 9.4 (SAS Institute Inc) and 
Microsoft Office Excel software (Microsoft Corp.).
2.9 | Ethical approval
Applicable national, international, and institutional guidelines for 
 studies involving live animals were followed. The Finnish national Animal 
Experiment Board, permit number: ESAVI/7482/04.10.07/2015 (date 
of approval 9.10.2015) approved this study. For samples purposefully 
collected for use in the NMR metabolomics project, written informed 
consent from animal owners was obtained, allowing the scientific 
use of samples and metadata. For the leftover laboratory samples, a 
consent for leftover sample material used for scientific purposes was 
given during analysis ordering.
3  | RESULTS
3.1 | Proton NMR spectroscopy quantitates 123 
measurands
The NMR platform was able to quantify 123 measurands, including 
extensive lipoprotein profiling, fatty acids, amino acids, albumin, cre-
atinine, and glycolysis- related metabolites, in canine serum/plasma 
F I G U R E  1   The measurands quantified by the nuclear magnetic resonance- based canine metabolomics platform. *not available from 
EDTA plasma samples. BCAA, Branched- chain amino acids; L- HDL, large HDL particles; L- LDL, large LDL particles; L- VLDL, large VLDL 
particles; S- HDL, small HDL particles; S- LDL, small LDL particles; S- VLDL, small VLDL particles; XL- HDL, very large HDL particles; XL- VLDL, 
Chylomicrons and very large VLDL particles
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(Figure 1). The sample failure rate was around 0.4%, with the most 
common cause being that the sample volume was too small. The 
per- metabolite failure rate was typically under 1%. However, meas-
urands having very low concentrations in healthy dogs, such as chy-
lomicrons and very large VLDL (XL- VLDL), large VLDL (L- VLDL), and 
HDL triglyceride variables, had 3%- 43% missing observations.
3.2 | Precision of the platform
We studied analytic precision using three biologically different dogs, 
with duplicate aliquots of each dog's sample analyzed once a day during 
a 20- day period (Table 2; Table S3). The aliquots from a senior dog suf-
fering from hyperadrenocorticism showed marked chylomicronemia 
and were thus excluded from method precision estimations. Outlier 
removal affected the interpretation of results slightly; thus, results 
were evaluated with outliers removed. In the main (nonchylomicrone-
mic) samples evaluated, 103/123 measurands reached all precision 
goals. Albumin, glucose, and creatinine did not reach the precision 
goal, CVBV, based on biological variation, but reached all other preci-
sion goals, including the CV% goal based on ASVCP Clinical Decision 
Limits (CVCDL), and the ST goal of being under 1/8 reference widths 
(STmax). Histidine, acetate, phenylalanine/tyrosine, and branched- chain 
amino acids (BCAA)/tyrosine met the precision goal of CV% under 
20% (CVBG) but did not meet the STmax goal. Ten of 123 measurands 
did not reach the CVBG goal but reached the STmax goal. All of these 
measurands from the tested samples were lipid measurands with high 
inter- individual biological variation, large RI widths, and were in low 
concentrations. The CVBG goal was thus regarded as inappropriate for 
these measurands since the variation of these measurand concentra-
tions was not considered to affect clinical decision- making.
Chylomicronemia caused imprecision in multiple lipid mea-
surands, creatinine, leucine, and phenylalanine. Glutamine precision 
was nonevaluable since the olefin oligomer gel in the sample tubes 
inhibited glutamine quantification. The precision of XL- VLDL phos-
pholipids was nonevaluable due to multiple missing observations 
caused by very low measurand concentrations physiologically. The 
concentration of XL- VLDL particles was too low in the nonlipemic 
dogs for reliable precision estimations.
3.3 | Interference screen
We studied the interference of hemolysis, lipemia, and unconju-
gated and conjugated bilirubin using triplicate samples of two differ-
ent hemolysis and bilirubinemia test pools and one lipemia test pool 
(Table S4; Table 3). Hemolysis interfered with the quantitation of 
albumin and certain lipids. No interference was observed for uncon-
jugated bilirubin. The only measurands exceeding the interference 
cutoff for conjugated bilirubin were L- VLDL cholesterol, L- VLDL 
esterified cholesterol, and S- HDL triglycerides. However, multiple 
missing observations were present, and thus, interference could not 
be inferred. Lipemia affected the quantitation of GlycA due to the 
contribution of lipid to the GlycA signal. However, the concentration 
of GlycA remained above the reference interval after the removal 
of lipids, indicating that lipemia was not the sole cause for the in-
creased GlycA concentration in the lipemia pool.
3.4 | Method comparison
Using 999 canine clinical samples, we evaluated whether the results of 
routine clinical chemistry measurands using the NMR metabolomics 
platform were comparable with the results obtained using conventional 
clinical chemistry methods (Table 4; Table S5). The tested measurands 
were glucose, lactate, creatinine, albumin, cholesterol, and triglycerides. 
The tested samples covered the clinical concentration ranges for all 
measurands. The comparison plots showed satisfactory agreement be-
tween the two methods for all measurands. In some measurands, loga-
rithm transformation showed better agreement than the initial data.
Glucose, lactate, and albumin measurements reached the TEa 
goals based on ASVCP Clinical Decision Limits,25 indicating that the 
two methods can be used interchangeably without affecting clinical 
decision- making (Table 4). The bias percentage of creatinine, cho-
lesterol, and triglycerides was too high for the measurands to reach 
the TEa goals based on Clinical Decision Limits, meaning that the 
two methods could not be used interchangeably. Values obtained by 
the conventional method could be evaluated against values obtained 
by the NMR method using the slope and intercept calculated with 
Deming regression (Table S5).
3.5 | The effect of sample storage on 
measurand stability
All evaluated measurands remained stable in refrigerated tempera-
tures for 7 days (Table 5, Table S1). Most of the measurands also re-
mained stable at room temperature for 7 days. Unstable measurands 
at room temperature were the histidine, isoleucine, glutamine, tyros-
ine, and phenylalanine amino acids, acetate, triglycerides, certain lipo-
protein particle constituent concentrations, as well as the fatty acid, 
docosapentaenoic acid. The stability of all amino acids other than glu-
tamine was better in EDTA plasma than in serum. Glutamine concen-
trations changed significantly at 4 days of storage at room temperature 
in EDTA plasma samples and 7 days of storage in serum samples. The 
acceptable change limit (ACL) of glutamine and XL- VLDL phospholipids 
could not be calculated using the mean coefficient of variation (CVa) 
analysis since these were not available from the precision study. The 
changes observed in triglyceride concentrations at room temperature 
originated from their computational quantitation based on the lipopro-
tein particle distribution and lipid quantity in the lipoprotein particle 
core and outer surface. These are slightly affected by sample storage at 
room temperature, thus affecting triglyceride quantitation.
All of the evaluated measurands were stable at −80℃ for 
12 months. Storage at −20℃ affected certain lipoprotein particles 
and composition, certain fatty acids, citrate, acetate, and GlycA. 
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TA B L E  2   Measurands exceeding one or more of their within- laboratory precision goals using a nuclear magnetic resonance platform in 
dogs
Measurand Dog Nmiss Mean
Precision Precision goals
CV% ST CVBV (%) CVCDL (%) CVBG (%) STmax
Glucose mmol/L adu 0 4.51 5.0 0.23 3.9a  10.0 0.30
Creatinine µmol/L pup 0 61.8 6.2 3.9 5.9a  10.0 9.0
Creatinine µmol/L adu 0 54.8 7.5 4.1 5.9a  10.0 9.0
Albumin g/L pup 0 28.8 2.1 0.6 1.0a  7.5 0.9
Albumin g/L adu 0 29.8 2.1 0.6 1.0a  7.5 0.9
Acetate µmol/L pup 0 33.1 7.4 2.5 20 2.0a 
Acetate µmol/L adu 0 31.0 12.3 3.8 20 2.0a 
Histidine µmol/L pup 0 73.4 9.9 7.3 20 5.6a 
BCAA/Tyrosine adu 0 8.0 10.2 0.8 20 0.7a 
Phenylalanine/Tyrosine adu 0 0.8 10.2 0.1 20 0.1a 
HDL triglycerides 
mmol/L
pup 0 0.023 22.3 0.005 20a  0.009
XL- VLDL lipids mmol/L pup 1 0.024 39.7 0.010 20a  0.033
XL- VLDL lipids mmol/L adu 0 0.016 51.2 0.008 20a  0.033
XL- VLDL cholesterol 
mmol/L
pup 1 0.001 37.9 0.000 20a  0.007
XL- VLDL cholesterol 
mmol/L
adu 0 0.007 24.9 0.002 20a  0.007
XL- VLDL free 
cholesterol mmol/L
adu 1 0.003 30.7 0.001 20a  0.006
XL- VLDL triglycerides 
mmol/L
pup 1 0.023 40.5 0.009 20a  0.021
L- VLDL triglycerides 
mmol/L
adu 0 0.108 20.0 0.022 20a  0.052
XL- HDL triglycerides 
mmol/L
pup 0 0.009 20.5 0.002 20a  0.003
XL- HDL triglycerides 
mmol/L
adu 1 0.010 20.1 0.002 20a  0.003
L- HDL triglycerides 
mmol/L
pup 0 0.012 22.2 0.003 20a  0.003
S- HDL triglycerides 
mmol/L
adu 4 0.004 49.5 0.002 20a  0.004
L- VLDL phospholipids 
mmol/L
pup 2 0.009 60.8 0.005 20a  0.013
L- VLDL phospholipids 
mmol/L
adu 0 0.030 27.9 0.008 20a  0.013
Note: The method's within- laboratory precision, expressed as coefficient of variation (CV%) and standard deviation (ST), was evaluated against 
precision goals CVBV, CVCDL, CVBG, and STmax. CVBV represents the biological variation- based goal for CV%.
24 CVCDL represents the goal for CV% 
based on total allowable error.25 CVBG was used as the CV% goal for measurands, for which CVBV and CVCDL goals were unavailable and represent 
the generally accepted laboratory error of 20% in metabolomics. STmax represents the goal for ST, set as 1/8 of the reference interval width. Precision 
was evaluated from the aliquots (n = 40) of the two dogs, puppy (pup) and adult (adu), with nonlipemic serum. Only lipid measurands with large 
reference interval width, and low concentrations in the tested samples, exceeded the CVBG goal. The CVBG goal was regarded inappropriate for these 
measurands in these conditions since the detected imprecision was not considered to affect clinical decision- making.
Abbreviations: L- HDL, large HDL particles; L- VLDL, large VLDL particles; S- HDL, small HDL particles; XL- HDL, very large HDL particles; XL- VLDL, 
Chylomicrons and very large VLDL particles.
Nmiss, number of missing observations; Mean, overall mean of the dog's measured aliquots’ measurand concentrations.
aPrecision goal exceeded.
     |  419OTTKA eT Al.
Citrate concentration was significantly (P < .05) changed at 1 week 
of −20℃ storage.
Stored heparinized plasma samples rarely reached a P- value of 
.05, even when the MPD exceeded the ACL. Statistically significant 
(P < .05) changes were also noted in other sample types.
Outlier removal affected the interpretation of serum and EDTA 
plasma results slightly; thus, those results were evaluated after out-
lier removal. In heparinized plasma, outliers could not be reliably 
identified due to the small sample size (n = 4).
3.6 | The effect of delayed plasma separation on 
measurand stability
We studied the effect of delayed plasma separation in 34 EDTA 
plasma samples, which had been stored as whole blood in the refrig-
erator for 24 or 48 hours before separating plasma (Table S6; Table 6). 
Outlier removal affected the interpretation of results slightly; thus, 
the results were evaluated after outlier removal. Prolonged con-
tact with red blood cells (RBCs) affected the concentration of many 
measurands. Significant changes (P <.05, MPD > ACL) after a 1- day 
contact with RBCs at refrigerated temperatures were observed for 
glucose and lactate. After 2 days of contact with RBCs, significant 
changes were observed in citrate, the amino acids, alanine, histidine, 
isoleucine, leucine, valine, phenylalanine, and tyrosine, and choles-
terol, triglycerides, and lipoprotein particles and their constituents. 
Glutamine values also changed significantly (P < .05) at 48 hours of 
storage in whole blood, but the MPD could not be evaluated against 
the ACL due to the missing ACL.
3.7 | Sample tube validation
We studied the differences of seven different sample tubes and the 
variability between two sample lots using samples from 20 client- 
owned dogs (Table S2). Outlier removal did not affect the interpreta-
tion of results; thus, results were evaluated without outlier removal.
First, the different sample tubes were compared with the primary 
reference tube (Vacuette Lithium Heparin). Most measurands showed 
comparable results for all tube types. Significant differences (P < .05) 
TA B L E  3   Measurands with detected interference
Interferent Measurand Dog Meanbase Meantest dc dobs dobs_lower
Lipemia Glycoprotein acetyls µmol/L 1000 1267 16 266 217
Hemolysis Albumin g/L 1 27.4 31.5 0.6 4.1 2.4
Hemolysis Albumin g/L 2 28.5 32.5 0.6 4.0 2.3
Hemolysis Triglycerides mmol/L 2 0.612 0.384 0.051 0.228 0.070
Hemolysis VLDL particles nmol/L 1 40 27 2 12 6
Hemolysis VLDL particle size nm 1 40.15 42.52 0.35 2.37 1.28
Hemolysis LDL particle size nm 1 22.30 21.91 0.04 0.39 0.27
Hemolysis VLDL cholesterol mmol/L 1 0.197 0.131 0.012 0.066 0.030
Hemolysis LDL triglycerides mmol/L 1 0.235 0.163 0.016 0.072 0.023
Hemolysis LDL triglycerides mmol/L 2 0.216 0.130 0.016 0.086 0.037
Hemolysis Docosahexaenoic acid mmol/L 2 0.236 0.162 0.014 0.074 0.029
Hemolysis Omega- 3 fatty acids mmol/L 2 0.772 0.575 0.043 0.197 0.064
Note: Interference was determined to be present, when the point estimate (dobs) exceeded the lower 95% confidence interval limit of the interference 
cutoff value (dobs_lower). The table only includes lipoprotein particle superclass results, lipoprotein subclass results are not included. N = 3 for all 
samples. Interference for conjugated and unconjugated bilirubin was also screened. No interference was detected for unconjugated bilirubin. The 
only measurands exceeding the interference cutoff for conjugated bilirubin were L- VLDL cholesterol, L- VLDL esterified cholesterol, and S- HDL 
triglycerides. However, multiple observations were missing for these measurands, and thus, interference could not be inferred.
dc, interference cutoff value; Meanbase, mean of the measurand results of the control replicates in the respective analyte units; Meantest, mean of the 
results of the replicate test samples in the respective analyte units.
TA B L E  4   Method interchangeability according to the method 
comparison study
Measurand Bias (%) CVa (%) TEobs (%) TEa
Glucose 3.8 3.7 11 20
Lactate 4.6 3.2 11 40
Creatinine 15.7 6.9 29* 20
Albumin 3.1 2.1 7 15
Cholesterol 23.4 2.9 29* 20
Triglycerides 29.3 8.6 46* 25
Note: Nuclear magnetic resonance (NMR) results of the clinical 
chemistry measurands included on the NMR platform compared 
with conventional clinical chemistry analysis methods. Bias was only 
evaluated as a measure for method interchangeability since results 
obtained by the conventional methods cannot be viewed as true values 
of the measurands. The results were determined to be interchangeable, 
if the observed total error (TEobs) was below the total allowable error 
(TEa) based on clinical decision limits.
25
CVa, Mean CV% of the two nonlipemic dogs from the precision study.
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with MPD > ACL were noted for citrate, glucose, lactate, and GlycA, 
and significant differences (P < .05) with MPD < ACL were observed 
for glutamine, histidine, pyruvate, and acetate. Glutamine showed a sig-
nificant difference (P < .05), but its ACL was not available. Most of the 
variability between tubes was observed between serum and plasma.
Second, measurand values in all serum tubes were compared with 
the reference serum tube (Vacuette Z Serum Clot Activator). All serum 
tubes showed comparable results with the serum reference tube.
The only lot- to- lot variability was observed in MiniCollect Serum 
gel tubes for glutamine and GlycA. Results obtained with both of 
these tube lots remained comparable to the reference serum tube 
(Vacuette Z Serum Clot Activator). In the MiniCollect Serum gel 
tubes, the two lots represented tubes of the old- type (lot A) and 
new- type (lot B) tubes; the physical appearance of the tube changed, 
but the constituents of the tube remained the same.
3.8 | Reference intervals for puppies, adult, and 
senior dogs
We determined the RIs of the nuclear magnetic resonance method for 
123 measurands in serum and heparinized plasma samples (Table 7). 
Raw, unrounded RIs and their 90% CI are presented in Table S7.
In certain lipoprotein measurands, such as the XL- VLDL vari-
ables, the concentration in healthy animals was very low, causing 
highly skewed distributions. Also, automatic quality control rejection 
of extremely low values caused an inability to calculate CIs with the 
nonparametric method used. For these measurands, the lower refer-
ence limit was rounded to 0. For a multitude of measurands, the 90% 
CI width was > 20% of the RI width due to skewed or heavy- tailed 
distributions. This was especially observed in RIs for puppies and 
senior dogs, where the n count was lower (n < 170) than in the adult 
TA B L E  5   Critical storage times for measurands affected by certain storage conditions in at least one sample type
Measurand Temperature Storage timeSerum (p) Storage timeEDTA (p) Storage timeHP (p)
Glutamine RT 7 da  (0.00*) 4 da  (0.04*) 4 da  (0.11)
Histidine RT 3 d (0.00*) NO 3 d (0.03*)
Isoleucine RT 2 d (0.04*) NO 4 d (0.20)
Phenylalanine RT 3 d (0.00*) NO 7 d (0.06)
Tyrosine RT 3 d (0.01*) NO NO
HDL triglycerides RT 2 d (0.01*) 4 d (0.07) 4 d (0.20)
LDL triglycerides RT 2 d (0.01*) 4 d (0.02*) 2 d (0.20)
VLDL triglycerides RT 2 d (0.00*) 2 d (0.04*) 4 d (0.11)
Triglycerides RT 24 h (0.04*) 2 d (0.02*) 2 d (0.20)
Acetate RT 4 d (0.02*) 7 d (0.00*) 4 d (0.03*)
Docosapentaenoic acid RT 7 d (0.03*) NE 7 d (0.20)
Citrate −20℃ 1 wk (0.00
*) NO — 
Acetate −20℃ 3 mo (0.00
*)b  6 mo (0.00*) — 
Glycoprotein acetyls −20℃ 1 mo (0.00
*) 1 month (0.01*) — 
Omega- 3 fatty acids −20℃ 6 mo (0.02
*) NE — 
HDL particle size −20℃ 3 mo (0.04
*) 3 mo (0.03*) — 
HDL particles −20℃ 6 mo (0.00
*) 6 mo (0.00*) — 
LDL lipids −20℃ NE 6 mo (0.03
*) — 
LDL particles −20℃ NE 6 mo (0.03
*) — 
LDL cholesterol −20℃ NE 6 mo (0.03
*) — 
VLDL particles −20℃ 6 mo (0.04
*) 6 mo (0.01*) — 
Note: The storage time presented in the table represents the time point, where statistically significant changes (two- sided Wilcoxon exact test 
P < .05), with a mean percentage deviation (MPD) exceeding the acceptable change limit (ACL) are first observed. In sample types where statistical 
significance was not observed (P ≥ .05), the storage times represent the time point, where the MPD first exceeds the ACL. This table includes only 
primary measurands. Lipoprotein particle subclasses are not included. Stability at −20 and −80℃ was not studied in heparinized plasma. nserum = 7, 
nEDTA = 7, nHP = 4.
NE, not evaluable due to discrepancies in P- values and MPD vs ACL. Results in other sample types should be consulted until further studies are 
conducted.
Abbreviations: NO, no change observed; RT, room temperature.
a ACL unknown, evaluated only as P < .05, time in heparinized plasma represents the time, where a change in magnitude similar to that in serum and 
EDTA plasma is observed.
bAt 6 mo of storage, MPD returned below the ACL and P > .05.
*P < .05.
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dogs. However, we also saw this phenomenom in RIs with very high 
n counts (n > 800).
4  | DISCUSSION
Metabolomics is a rapidly growing field, with considerable potential 
for numerous clinical and scientific applications. NMR spectroscopy 
is a promising metabolomics method for clinical use due to its quan-
titative nature, high throughput, accuracy, and speed.16 In this study, 
we validated a novel, cost- effective NMR metabolomics platform 
in dogs. A similar approach has been demonstrated previously and 
widely used in people.16 The platform quantifies 123 measurands 
from 100 µL samples of serum, heparinized plasma, EDTA plasma, or 
citrated plasma. The throughput for one device is ~200 samples per 
24 hours, making around 70 000 samples per year. The turnaround 
time is currently 5 days and can be reduced. These characteristics 
make it a potentially new high- throughput method to facilitate vet-
erinary research and clinical diagnostics, with significant implica-
tions regarding the treatment, care, and well- being of dogs.
Using a new laboratory method in clinics requires excellent 
methodologic precision. The precision of the NMR metabolomics 
platform is generally outstanding, as demonstrated by our results, 
showing that most of the measurands reached all respective pre-
cision goals. However, for histidine, acetate, phenylalanine/tyro-
sine, and BCAA/tyrosine, further studies are needed in diseased 
animals to conclude whether measurement imprecision affects 
clinical use.
The analytical method used should always be considered when 
evaluating laboratory results against treatment guidelines and RIs.14 
A linear relationship between the conventional and NMR method 
was observed for all evaluated clinical chemistry measurands: glu-
cose, lactate, creatinine, albumin, triglycerides, and cholesterol. 
However, the results of these measurands cannot be evaluated in-
terchangeably between methods. Triglycerides showed the highest 
between- method variability. This can be explained by differences 
in methodology (NMR measures triglycerides within lipoprotein 
particles vs the conventional method interacts solely with the tri-
glyceride molecule), sample handling (immediate analysis with the 
conventional method vs freezing of NMR aliquots, one sample batch 
partly thawed during shipment), and biological characteristics (effect 
of lipemia on precision, causing higher variability in high triglyceride 
concentrations).
Correct preanalytical measures are considered essential for 
the integrity of laboratory results.39,40 For instance, an appropri-
ate sample drawing technique is crucial to avoid hemolysis, fasting 
before sample drawing is critical to avoid lipemia, and prompt RBC 
separation is needed to avoid prolonged RBC metabolism, which 
all impact NMR analytic results. The profound impact of chylomi-
cronemia on method precision was caused by matrix heterogeneity 
due to chylomicron cream layer formation, which could be reduced 
by sample mixing. In addition to glycolysis- related metabolites, 
amino acids were affected by prolonged contact with RBC. This 
might explain why amino acid stability was better in our storage 
study using plasma and serum samples than in previous studies 
using whole blood.41,42
It is critical to use sample storage and shipping conditions that 
allow for sample quality preservation. All tested measurands re-
mained stable at refrigerator temperature for 1 week, making it 
the optimal short- term storage temperature for samples. Storage at 
room temperature should be avoided. The stability of most amino 
acids was better in EDTA plasma than in serum at room temperature, 
which has been previously reported.42 The gold standard for long- 
term storage is immediate freezing to −80℃ after serum/plasma 
separation and avoiding additional freeze- thaw cycles.43 This was 
also the optimal storage protocol according to this study, with all 
measurands remaining stable for 1 year at −80℃. Two weeks of stor-
age at −20℃ was suitable for most measurands.
Determination of RIs is an important prerequisite for the clinical 
use of a new laboratory method. We determined the RIs for 123 
measurands, most of which have not been previously published. The 
sample tube validation study suggested that the sample tubes of 
TA B L E  6   Critical storage times as whole blood for measurands 
affected by storage as whole blood
Measurand Storage time (p)
Glucose 24 h (0.00)
Lactate 24 h (0.00)
Citrate 48 h (0.00)
Alanine 48 h (0.00)
Glutamine 48 ha  (0.00)
Histidine 48 h (0.00)
Isoleucine 48 h (0.00)
Leucine 48 h (0.01)
Valine 48 h (0.00)
Phenylalanine 48 h (0.00)
Tyrosine 48 h (0.00)
HDL lipids 48 h (0.03)
HDL particles 48 h (0.00)
LDL diameter 48 h (0.00)
VLDL diameter 48 h (0.04)
Cholesterol 48 h (0.02)
HDL cholesterol 48 h (0.00)
Esterified cholesterol 48 h (0.00)
Triglycerides 48 h (0.00)
VLDL triglycerides 48 h (0.00)
Note: The storage time presented in the table represents the time point, 
where statistically significant changes (two- sided Wilcoxon exact test 
P < .05) together with a mean percentage deviation (MPD) exceeding 
the acceptable change limit (ACL) are first observed. n = 34. This table 
includes only primary measurands. Lipoprotein particle subclasses are 
not included.
aACL unknown.
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TA B L E  7   Measurand reference intervals determined on a canine nuclear magnetic resonance- based metabolomics platform
Measurand HP all dogs S all dogs S puppy S adult S senior
Glucose mmol/L 4.3- 6.8 4.4- 6.8 4.7- 7.3 4.4- 6.6 4.0- 6.1
Lactate mmol/L 0.7- 3.0 1.1- 3.6 1.3- 2.9 1.1- 3.6 1.1- 4.2
Creatinine µmol/L 40- 99 32- 103 21- 96 40- 108 37- 104
Albumin mg/dL 26- 32 25- 32 22- 31 26- 32 26- 32
Cholesterol mmol/L 3.8- 10.4 3.6- 10.3 3.8- 10.1 3.6- 10.3 3.5- 10.6
Triglycerides mmol/L 0.22- 0.97 0.19- 1.00 0.18- 0.76 0.19- 0.97 0.19- 1.13
Pyruvate µmol/L 29- 155 11- 107 9- 96 11- 111 13- 109
Citrate µmol/L 63- 122 61- 123 57- 115 61- 124 62- 128
Acetate µmol/L 19- 36 21- 37 22- 40 21- 37 20- 37
Alanine µmol/L 214- 584 216- 597 205- 504 205- 583 244- 650
Glycine µmol/L 147- 466 130- 454 145- 594. 127- 381 128- 403
Glutamine µmol/L 570- 919 640- 1015 642- 997 659- 1028 616- 1014
Histidine µmol/L 50- 91 53- 98 46- 93 55- 99 55- 97
Isoleucine µmol/L 33- 80 37- 89 30- 80 38- 92 38- 87
Leucine µmol/L 74- 168 83- 185 67- 159 89- 186 94- 186
Valine µmol/L 107- 245 113- 251 80- 236 119- 260 124- 253
Phenylalanine µmol/L 32- 64 30- 65 28- 66 29- 64 34- 66
Tyrosine µmol/L 39- 85 41- 89 39- 83 41- 90 46- 93
BCAA µmol/L 222- 482 242- 515 178- 462 261- 524 251- 521
Glycine/BCAA 0.3- 1.4 0.3- 1.5 0.4- 3.0 0.3- 1.2 0.3- 1.2
BCAA/Tyrosine 3.7- 9.5 3.8- 9.2 3.8- 8.3 3.9- 9.5 3.5- 8.6
Phenylalanine/tyrosine 0.6- 1.2 0.5- 1.0 0.5- 1.1 0.5- 1.0 0.5- 1.0
Glycine/valine 0.6- 2.6 0.7- 3.0 0.9- 6.8 0.7- 2.5 0.7- 2.6
Alanine/BCAA 0.7- 2.0 0.6- 1.6 0.6- 1.4 0.5- 1.6 0.6- 1.8
Alanine/valine 1.3- 3.7 1.2- 3.5 1.3- 3.0 1.1- 3.5 1.3- 3.8
VLDL lipids mmol/L 0.1- 1.1 0.1- 1.2 0.1- 0.8 0.1- 1.1 0.1- 1.3
VLDL particles nmol/L 15- 54 12- 54 14- 45 12- 51 12- 67
LDL lipids mmol/L 0.5- 3.7 0.7- 3.7 0.7- 3.7 0.7- 3.6 0.7- 4.5
LDL particles nmol/L 200- 1400 240- 1300 270- 1300 240- 1300 240- 1600
HDL lipids mmol/L 7.7- 14.6 6.9- 15.1 7.2- 15.0 6.9- 15.1 6.6- 15.3
HDL particles nmol/L 32 000- 57 000 30 000- 58 000 33 000- 58 000 30 000- 59 000 28 000- 58 000
VLDL particle size nm 35.8- 43.6 35.2- 43.8 35.1- 41.7 35.3- 43.8 35.4- 44.4
LDL particle size nm 22.1- 23.9 22.2- 23.5 22.3- 23.5 22.2- 23.4 22.2- 23.5
HDL particle size nm 10.1- 10.7 10.1- 10.7 10.1- 10.6 10.0- 10.6 10.1- 10.7
VLDL cholesterol mmol/L 0.03- 0.31 0.03- 0.31 0.03- 0.23 0.03- 0.29 0.03- 0.36
LDL cholesterol mmol/L 0.16- 2.35 0.28- 2.27 0.30- 2.24 0.28- 2.21 0.28- 2.85
HDL cholesterol mmol/L 3.6- 8.0 3.2- 7.9 3.6- 7.9 3.2- 7.9 3.0- 8.0
Esterified cholesterol mmol/L 3.1- 8.2 2.9- 8.1 3.2- 8.0 2.9- 8.1 2.9- 8.4
Free cholesterol mmol/L 0.7- 2.2 0.6- 2.2 0.7- 2.0 0.6- 2.2 0.6- 2.4
VLDL triglycerides mmol/L 0.02- 0.70 0.00- 0.70 0.00- 0.44 0.00- 0.69 0.00- 0.86
LDL triglycerides mmol/L 0.13- 0.30 0.13- 0.31 0.15- 0.33 0.13- 0.29 0.14- 0.27
HDL triglycerides mmol/L 0.01- 0.08 0.00- 0.08 0.00- 0.04 0.00- 0.07 0.01- 0.09
Glycoprotein acetyls µmol/L 532- 964 597- 1028 611- 996 596- 1005 605- 1129
Palmitic acid mmol/L 1.9- 3.5 1.8- 3.6 1.8- 3.4 1.8- 3.6 1.8- 3.9
Stearic acid mmol/L 1.9- 3.8 1.7- 3.8 1.8- 3.7 1.7- 3.9 1.7- 4.0
(Continues)
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Measurand HP all dogs S all dogs S puppy S adult S senior
Oleic acid mmol/L 1.1- 2.5 1.3- 2.8 1.3- 2.5 1.3- 2.8 1.3- 3.2
Linoleic acid mmol/L 2.7- 5.7 2.5- 5.9 2.5- 5.1 2.5- 5.9 2.5- 6.2
Arachidonic acid mmol/L 1.6- 3.7 1.4- 3.6 1.5- 3.7 1.4- 3.6 1.3- 3.7
Docosapentaenoic acid mmol/L 0.1- 0.3 0.1- 0.4 0.1- 0.3 0.1- 0.4 0.1- 0.4
Docosahexaenoic acid mmol/L 0.1- 0.9 0.1- 0.7 0.1- 0.8 0.1- 0.7 0.1- 0.8
Omega- 3 fatty acids mmol/L 0.4- 1.8 0.4- 1.6 0.4- 1.6 0.4- 1.6 0.5- 1.8
Omega- 6 fatty acids mmol/L 4.5- 9.6 4.1- 9.8 4.2- 9.3 4.1- 9.6 3.9- 10.6
Polyunsaturated fatty acids mmol/L 5.2- 10.8 4.7- 11.1 4.8- 10.6 4.7- 11.0 4.6- 12.0
Saturated fatty acids mmol/L 3.9- 7.2 3.6- 7.4 3.6- 6.8 3.6- 7.5 3.5- 7.7
Total fatty acids mmol/L 10.5- 20.4 9.7- 21.0 9.8- 20.0 9.7- 21.2 9.3- 22.5
Palmitic acid % 15.9- 19.8 16- 20 16- 19 16- 19 16- 20
Stearic acid % 17.5- 19.5 17.3- 19.4 17.5- 19.3 17.4- 19.5 17.1- 19.4
Oleic acid % 9.2- 14.2 10.7- 15.1 10.6- 14.2 10.9- 15.1 10.9- 15.7
Linoleic acid % 23.9- 29.4 24.1- 28.6 23.3- 27.5. 24.5- 28.6 24.7- 28.7
Arachidonic acid % 13.6- 20.7 13.2- 20.1 15.0- 20.7. 13.1- 19.9 12.7- 19.2
Docosapentaenoic acid % 0.9- 1.9 1.1- 2.0 1.1- 1.9 1.1- 1.9 1.1- 2.0
Docosahexaenoic acid % 0.9- 6.2 0.7- 4.8 1.0- 5.2 0.7- 4.7 0.6- 5.0
Omega- 3 fatty acids % 3- 12 3- 10 3- 11 3- 11 4- 11
Omega- 6 fatty acids % 43- 49 42- 48 42- 48 42- 48 42- 47
Polyunsaturated fatty acids % 48- 57 48- 55 48- 55 47- 55 47- 55
Saturated fatty acids % 34- 39 34- 38 34- 38 34- 38 33- 38
Omega- 6/omega- 3 fatty acids 3.5- 16.3 4.2- 13.4 4.1- 13.5 4.2- 14.2 4.0- 13.1
XL- VLDL particles nmol/L 0- 2 0- 1 0- 1 0- 1 0- 2
L- VLDL particles nmol/L 1- 15 0- 16 0- 11 0- 15 0- 19
S- VLDL particles nmol/L 11- 38 10- 39 13- 34 10- 37 10- 47
L- LDL particles nmol/L 79- 380 90- 370 110- 350 91- 380 83- 400
S- LDL particles nmol/L 89- 1000 140- 960 130- 940 130- 920 140- 1100
XL- HDL particles nmol/L 1- 6200 0- 5800 25- 5500 0- 5800 1- 6000
L- HDL particles nmol/L 21 000- 34 000 20 000- 34 000 20 000- 34 000 19 000- 35 000 18 000- 34 000
S- HDL particles nmol/L 11 000- 19 000 11 000- 20 000 11 000- 19 000 11 000- 20 000 10 000- 20 000
XL- VLDL lipids mmol/L 0- 0.3 0- 0.3 0- 0.2 0- 0.2 0- 0.4
L- VLDL lipids mmol/L 0- 0.6 0- 0.6 0- 0.4 0- 0.6 0- 0.7
S- VLDL lipids mmol/L 0.1- 0.4 0.1- 0.4 0.1- 0.3 0.1- 0.3 0.1- 0.4
L- LDL lipids mmol/L 0.2- 1.2 0.3- 1.2 0.3- 1.1 0.3- 1.2 0.3- 1.3
S- LDL lipids mmol/L 0.2- 2.6 0.3- 2.4 0.3- 2.4 0.3- 2.3 0.3- 2.9
XL- HDL lipids mmol/L 0.6- 5.2 0.6- 5.0 0.6- 4.7 0.6- 5.0 0.7- 5.2
L- HDL lipids mmol/L 5.4- 8.1 5.0- 8.3 5.0- 8.1 4.9- 8.3 4.8- 8.3
S- HDL lipids mmol/L 1.3- 2.1 1.3- 2.2 1.3- 2.1 1.3- 2.2 1.1- 2.2
XL- VLDL cholesterol mmol/L 0- 0.06 0- 0.06 0- 0.04 0- 0.06 0- 0.08
L- VLDL cholesterol mmol/L 0- 0.13 0- 0.13 0- 0.08 0- 0.12 0- 0.15
S- VLDL cholesterol mmol/L 0.01- 0.14 0.02- 0.15 0.02- 0.11 0.02- 0.14 0.02- 0.18
L- LDL cholesterol mmol/L 0.03- 0.70 0.07- 0.68 0.11- 0.61 0.07- 0.68 0.07- 0.76
S- LDL cholesterol mmol/L 0.09- 1.64 0.16- 1.53 0.16- 1.50 0.16- 1.48 0.18- 1.88
XL- HDL cholesterol mmol/L 0.3- 3.0 0.2- 2.8 0.3- 2.9 0.2- 2.7 0.2- 2.9
L- HDL cholesterol mmol/L 2.6- 4.3 2.3- 4.4 2.5- 4.3 2.3- 4.5 2.2- 4.4
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the same type are generally comparable. Since sample type char-
acteristics, such as prolonged contact with RBCs in serum, caused 
slightly different results in serum and plasma, RIs for the sample type 
in question should be used. It should also be noted that glycine and 
pyruvate cannot be quantified in EDTA plasma, and glutamine is not 
quantifiable from oligofin oligomer gel tubes.
Limitations of this study are that the precision and interfer-
ence studies did not include samples at clinical decision levels for 
all measurands. Due to the extensiveness of the NMR platform, 
acquiring these samples would have been extremely difficult. The 
sample numbers, especially in heparinized plasma, were a limitation 
of the storage study. The interference study for hemolysis and li-
pemia should be continued with a dose- response series of interfer-
ent concentrations.15,30 Limitations of the method comparison study 
include the lack of a reference method, generating results that could 
be viewed as true measurand values.
Measurand HP all dogs S all dogs S puppy S adult S senior
S- HDL cholesterol mmol/L 0.5- 1.0 0.5- 1.0 0.6- 1.0 0.5- 1.0 0.5- 1.0
XL- VLDL esterified cholesterol mmol/L 0- 0.03 0- 0.03 0- 0.02 0- 0.03 0- 0.03
L- VLDL esterified cholesterol mmol/L 0- 0.05 0- 0.06 0- 0.04 0- 0.05 0- 0.07
S- VLDL esterified cholesterol mmol/L 0- 0.09 0.01- 0.09 0.01- 0.08 0.01- 0.09 0.01- 0.11
L- LDL esterified cholesterol mmol/L 0.01- 0.51 0.03- 0.49 0.05- 0.43 0.02- 0.48 0.02- 0.55
S- LDL esterified cholesterol mmol/L 0.05- 1.14 0.10- 1.09 0.10- 1.06 0.10- 1.06 0.12- 1.35
XL- HDL esterified cholesterol mmol/L 0.2- 2.3 0.2- 2.1 0.2- 2.1 0.2- 2.1 0.2- 2.3
L- HDL esterified cholesterol mmol/L 2.3- 3.7 2.0- 3.8 2.2- 3.7 2.0- 3.8 1.9- 3.8
S- HDL esterified cholesterol mmol/L 0.4- 0.8 0.4- 0.8 0.5- 0.8 0.4- 0.8 0.4- 0.8
XL- VLDL free cholesterol mmol/L 0- 0.05 0- 0.05 0- 0.03 0- 0.04 0- 0.05
L- VLDL free cholesterol mmol/L 0- 0.08 0- 0.08 0- 0.05 0- 0.07 0- 0.10
S- VLDL free cholesterol mmol/L 0.01- 0.05 0.01- 0.06 0.01- 0.05 0.01- 0.05 0.01- 0.07
L- LDL free cholesterol mmol/L 0.03- 0.20 0.04- 0.20 0.05- 0.18 0.04- 0.20 0.04- 0.21
S- LDL free cholesterol mmol/L 0.04- 0.48 0.05- 0.45 0.06- 0.45 0.05- 0.43 0.05- 0.53
XL- HDL free cholesterol mmol/L 0.1- 0.7 0.1- 0.6 0.1- 0.6 0.1- 0.6 0.1- 0.6
L- HDL free cholesterol mmol/L 0.3- 0.6 0.3- 0.6 0.3- 0.6 0.3- 0.6 0.3- 0.6
S- HDL free cholesterol mmol/L 0.1- 0.2 0.1- 0.2 0.1- 0.2 0.1- 0.2 0.1- 0.2
XL- VLDL triglycerides mmol/L 0- 0.22 0- 0.17 0- 0.13 0- 0.17 0- 0.24
L- VLDL triglycerides mmol/L 0.01- 0.41 0.01- 0.42 0.00- 0.27 0.01- 0.39 0.01- 0.49
S- VLDL triglycerides mmol/L 0.03- 0.16 0.02- 0.16 0.02- 0.13 0.01- 0.15 0.02- 0.19
L- LDL triglycerides mmol/L 0.11- 0.24 0.10- 0.24 0.11- 0.26. 0.09- 0.23 0.10- 0.22
S- LDL triglycerides mmol/L 0.02- 0.07 0.03- 0.07 0.03- 0.08 0.03- 0.07 0.03- 0.07
XL- HDL triglycerides mmol/L 0- 0.02 0- 0.02 0- 0.02 0- 0.02 0- 0.03
L- HDL triglycerides mmol/L 0.01- 0.03 0- 0.03 0- 0.02 0- 0.03 0- 0.04
S- HDL triglycerides mmol/L 0- 0.04 0- 0.03 0- 0.02 0- 0.03 0- 0.04
XL- VLDL phospholipids mmol/L 0- 0.05 0- 0.05 0- 0.04 0- 0.05 0- 0.09
L- VLDL phospholipids mmol/L 0- 0.09 0- 0.11 0- 0.06 0- 0.10 0- 0.15
S- VLDL phospholipids mmol/L 0.01- 0.07 0.01- 0.08 0.01- 0.06 0- 0.08 0.01- 0.10
L- LDL phospholipids mmol/L 0.08- 0.33 0.08- 0.32 0.09- 0.33 0.07- 0.30 0.08- 0.35
S- LDL phospholipids mmol/L 0.08- 0.87 0.12- 0.84 0.12- 0.80 0.12- 0.80 0.12- 1.01
XL- HDL phospholipids mmol/L 0.35- 2.27 0.33- 2.22 0.32- 1.97 0.30- 2.21 0.34- 2.37
L- HDL phospholipids mmol/L 2.65- 3.92 2.48- 3.94 2.61- 3.79 2.44- 3.95 2.56- 4.01
S- HDL phospholipids mmol/L 0.74- 1.18 0.72- 1.19 0.76- 1.14 0.72- 1.19 0.67- 1.21
Note: This table presents the reference intervals for all measurands in serum and heparinized plasma. HP all dogs n = 269, S all dogs n = 865, S puppy 
n = 152, S adult n = 545, S senior n = 168.
Abbreviations: BCAA, Branched- chain amino acids; HP, heparinized plasma; L- HDL, large HDL particles; L- LDL, large LDL particles; L- VLDL, large 
VLDL particles; S, serum; S- HDL, small HDL particles; S- LDL, small LDL particles; S- VLDL, small VLDL particles; XL- HDL, very large HDL particles; 
XL- VLDL, Chylomicrons and very large VLDL particles.
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Linearity was not assessed since NMR is considered a primary 
ratio method. Its linearity is considered inherently outstanding since 
signal intensity is directly proportional to the number of nuclei caus-
ing the specific resonance. Detection limits were not determined 
since low concentrations of the included measurands are not consid-
ered clinically significant.
Owing to the advantages of quantitative results, high through-
put, and reproducibility, the developed NMR- based metabolomics 
platform validated in this study holds great potential for numerous 
clinical and research applications in veterinary medicine. The per-
formance of the NMR testing platform is generally outstanding, and 
routine blood drawing and processing guidelines ensure the integ-
rity of the results. The established metabolomics panel includes a 
wide representation of measurands from various molecular groups, 
including amino acids, fatty acids, glycolysis- related metabolites, 
and lipoproteins, enabling the comprehensive evaluation of the met-
abolic state of an individual.
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